Table 3.
Sex | Prediabetic Status | Time | Sex X prediabetes | Prediabetes X time | Sex X Time | Sex X Prediabetes X time | |||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
b | SE | p | b | SE | p | b | SE | p | b | SE | p | b | SE | p | b | SE | p | b | SE | p | |
AD biomarker | |||||||||||||||||||||
HV/IV | −0.27 | 0.09 | 0.003 | −0.14 | 0.09 | 0.13 | −0.007 | 0.001 | <0.001 | 0.11 | 0.18 | 0.53 | 0.001 | 0.001 | 0.51 | 0.001 | 0.001 | 0.33 | 0.001 | 0.002 | 0.71 |
CMRglu | −0.03 | 0.01 | 0.001 | −0.04 | 0.01 | 0.001 | −0.002 | 0.0002 | <0.001 | 0.03 | 0.02 | 0.10 | 0.0004 | 0.0002 | 0.05 | 0.0004 | 0.0002 | 0.05 | −0.3 × 10−4 | 0.0004 | 0.93 |
p-tau/ Aβ ratio |
−0.003 | 0.003 | 0.20 | −0.002 | 0.003 | 0.36 | 0.0001 | 0.3 × 10−4 | 0.003 | 0.005 | 0.003 | 0.17 | 0.0001 | 0.6 × 10−4 | 0.07 | 0.5 × 10−4 | 0.5 × 10−4 | 0.31 | −0.0001 | 0.0001 | 0.26 |
AD cognitive markers | |||||||||||||||||||||
AVLT z-score |
−0.36 | 0.05 | <0.001 | 0.02 | 0.05 | 0.72 | −0.004 | 0.0007 | <0.001 | −0.12 | 0.11 | 0.27 | 0.0002 | 0.001 | 0.90 | 0.002 | 0.001 | 0.18 | −0.003 | 0.003 | 0.24 |
TMT Part B z-score | −0.18 | 0.12 | 0.14 | −0.23 | 0.14 | 0.10 | −0.009 | 0.002 | <0.001 | 0.47 | 0.18 | 0.01 | −0.003 | 0.002 | 0.27 | 0.001 | 0.002 | 0.63 | −0.002 | 0.005 | 0.70 |
BNT z- score |
0.20 | 0.08 | 0.03 | −0.19 | 0.09 | 0.03 | −0.006 | 0.001 | <0.001 | 0.29 | 0.18 | 0.10 | 0.002 | 0.003 | 0.55 | 0.002 | 0.003 | 0.41 | −0.001 | 0.005 | 0.84 |
Bolded values indicate statistical significance. All analyses included the following covariates: age, education, race, APOE4 status, body mass index, pulse pressure and history of cardiovascular events. Covariates were removed from the final model if not a significant predictor of the outcome. SE, standard error; HV/IV, hippocampal/intracranial volume × 103; CMRglu, cerebral metabolic glucose rate; AVLT, Rey Auditory Verbal Learning Test; TMT, Trail Making Test; BNT, Boston Naming Test.